<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="330">
  <stage>Registered</stage>
  <submitdate>20/12/2002</submitdate>
  <approvaldate>20/12/2002</approvaldate>
  <nctid>NCT00050817</nctid>
  <trial_identification>
    <studytitle>Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA)</studytitle>
    <scientifictitle>A Phase III, Multicenter, Multinational, Randomized, Parallel Group, Double-blind Trial of Clopidogrel Versus Placebo in High-risk Patients Aged 45 Years and Older, at Risk of Atherothrombotic Events, and Who Are Receiving Background Therapy Including Low-dose ASA.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>EFC4505</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Arteriosclerosis</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - clopidogrel (SR25990)

Treatment: drugs: clopidogrel (SR25990)


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Occurrence of myocardial infarction,stroke or cardiovascular death.</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>severe bleeding</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>INCLUSION:

        Be at least 45 years old and comply with at least one of the four categories of inclusion
        criteria:

          -  Combination of atherothrombotic risk factors (2 major or 3 minor or 1 major + 2 minor
             risk factors among those listed below)

        Major atherothrombotic risk factors

          -  Type I or II diabetes (under drug therapy)

          -  Diabetic nephropathy

          -  Ankle brachial index (ABI) &lt; 0.9

          -  Asymptomatic carotid stenosis &gt;= 70%

          -  At least one carotid plaque as evidenced by intima-media thickness (IMT)

        Minor atherothrombotic risk factors

          -  Systolic blood pressure (SBP) &gt;= 150 mmHg, despite appropriate therapy for at least 3
             months

          -  Primary hypercholesterolemia

          -  Current smoking &gt; 15 cigarettes per day

          -  Male &gt;= 65 years

          -  Female &gt;= 70 years

        and/or

          -  Documented cerebrovascular disease (TIA or IS within 5 years) and/or

          -  Documented coronary artery disease (stable angina with documented multivessel coronary
             disease, previous documented MI, multivessel PCI or CABG within 1 year, multivessel
             CABG older than 1 year associated with current angina) and/or

          -  Documented symptomatic PAD

        EXCLUSION:

          -  Absolute indication for the use of clopidogrel, high-dose aspirin (&gt;162 mg), NSAIDs,
             or oral anti-thrombotic drugs

          -  Absolute contraindication to the use of clopidogrel or aspirin

          -  Clinical conditions likely to interfere with follow-up leading to inability to
             complete the trial</inclusivecriteria>
    <inclusiveminage>45</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2002</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>15603</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/08/2005</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Sanofi-aventis Administrative Office - Macquarie Park</hospital>
    <postcode> - Macquarie Park</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Wien</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Diegem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Sao Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Laval</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Santiago</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Praha</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Horsholm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Helsinki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Athens</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Causeway Bay</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Kuala Lumpur</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Mexico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Gouda</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Lysaker</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Porto Salvo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Midrand</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Bromma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Geneva</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Istanbul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Guildford Surrey</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Sanofi</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>RATIONALE:

        -  Atherothrombosis is a progressive and generalized vascular disease resulting in events
           leading to myocardial infarction (heart attack), stroke, and vascular death.

        -  In patients at risk for this disease, it is characterized by an unpredictable, sudden
           disruption of atherosclerotic plaques, which may lead to total occlusion of artery due
           to formation of a clot. The use of aspirin (blood thinner agent) for reducing those
           major ischemic events is either indicated, or recommended by international guidelines.
           However, aspirin fails to prevent a high percentage of such life-threatening events.
           Therefore, more effective blood thinning therapy may provide additional clinical benefit
           to such patients.

        -  The results of the CURE trial in patients with unstable angina demonstrate the
           additional benefit of long-term treatment (up to one year) with clopidogrel, (a blood
           thinner agent), when administered in combination with standard therapy including
           aspirin. The purpose of CHARISMA is to investigate whether a similar clinical benefit of
           clopidogrel may apply to a broad population of high-risk patients receiving low-dose
           aspirin therapy. Such population includes patients with previous cardiovascular,
           neurovascular or peripheral arterial manifestations of atherothrombosis and patients
           with combinations of recognized risk factors for atherosclerosis.

      OBJECTIVES:

        -  To assess the efficacy of clopidogrel 75 mg once-daily by comparison with a placebo, in
           preventing cardiovascular morbidity/mortality. The study will compare the efficacy of
           the two regimens in preventing the occurrence of major cardiovascular complications
           (stroke, heart attack, cardiovascular death) in high-risk patients who are otherwise
           receiving low-dose aspirin therapy (75-162 mg daily).

        -  To evaluate the safety of clopidogrel in this population, and more specifically the
           incidence of fatal or severe bleeding (as per GUSTO definition), in order to estimate
           the global benefit of clopidogrel in this patient population.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00050817</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>ICD CSD</name>
      <address>Sanofi</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>